Non-radioimmunometric NT-ProBNP and BNP assays: Impact of diluent, age, gender, BMI;Corrélation BNP-NT-proBNP: Rôle du diluant, influence de l'âge, du sexe et de l'indice de masse corporelle

Annales de Biologie Clinique

Volumn 63, Issue 1, 2005, Pages 43-49

  Alibay, Y ^a   Schmitt, C ^a   Beauchet, A ^a   Dubourg, O ^a   Alexandre, J A ^a   Boileau, C ^a   Jondeau, G ^a   Puy, H ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Brain natriuretic peptide; Congestive heart failure; N terminal pro brain natriuretic peptide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NERVE PROTEIN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD; BODY MASS; CHEMOLUMINESCENCE; COMPARATIVE STUDY; DYSPNEA; ELECTROCHEMISTRY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SEXUAL DEVELOPMENT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHEMILUMINESCENT MEASUREMENTS; DYSPNEA; ELECTROCHEMISTRY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS;

EID: 13644267882     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chen HH, Burnett JC. The natriuretic peptides in heart failure : diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999 ; 111 : 406-16.
2. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995 ; 214 : 1175-83.
3. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (NT-proBNP) : a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997 ; 47 : 287-96.
4. Mc Donagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998 ; 351 : 9-13.
5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001 ; 37 : 379-85.
6. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 ; 347 : 161-7.
7. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol 2002 ; 40 : 976-82.
8. Luchner A, Burnett JC, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000 ; 18 : 1121-8.
9. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999 ; 10 : 537-40.
10. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin : new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998 ; 97 : 1921-9.
11. Masson S, Vago T, Baldi G, et al. Comparative measurement of N-Terminal pro-BNP and BNP in ambulatory patients with heart failure. Clin Chem Lab Med 2002 ; 40 : 761-3.
12. The task force on heart failure of the European society of cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995 ; 16 : 741-51.
13. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel AS. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002 ; 39 : 202-9.
14. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001 ; 39 : 571-88.
15. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994 ; 343 : 440-4.
16. Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999 ; 20 : 1736-44.
17. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999 ; 31 : 487-98.
18. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal probrain natriuretic peptide, brain natriuretic peptide and N-terminal proatrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001 ; 310 : 193-7.
19. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003 ; 338 : 107-15.
20. Stanek B, Frey B, Hulsamnn M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001 ; 38 : 436-42.
21. Cabanes L, Richaud-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001 ; 120 : 2047-50.
22. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice : the need for a new generation of immunoassay methods. Clin Chem 2000 ; 46 : 1529-34.
23. Smith H, Pickering RM, Stuthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly inpatients in general practice : observational study. Br Med J 2000 ; 320 : 906-8.